See more : Signing Day Sports, Inc. (SGN) Income Statement Analysis – Financial Results
Complete financial analysis of Caribou Biosciences, Inc. (CRBU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Caribou Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Maharashtra Seamless Limited (MAHSEAMLES.BO) Income Statement Analysis – Financial Results
- SRG Housing Finance Limited (SRGHFL.NS) Income Statement Analysis – Financial Results
- The Tinley Beverage Company Inc. (TNYBF) Income Statement Analysis – Financial Results
- Wharf (Holdings) Limited (0004.HK) Income Statement Analysis – Financial Results
- Coty Inc. (0I4A.L) Income Statement Analysis – Financial Results
Caribou Biosciences, Inc. (CRBU)
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 34.48M | 13.85M | 9.60M | 12.36M | 5.79M |
| Cost of Revenue | 112.08M | 3.64M | 984.00K | 34.43M | 23.64M |
| Gross Profit | -77.60M | 10.21M | 8.61M | -22.06M | -17.85M |
| Gross Profit Ratio | -225.07% | 73.71% | 89.75% | -178.50% | -308.34% |
| Research & Development | 112.08M | 82.23M | 52.26M | 34.43M | 23.64M |
| General & Administrative | 38.46M | 38.02M | 24.32M | 14.06M | 16.46M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 38.46M | 38.02M | 24.32M | 14.06M | 16.46M |
| Other Expenses | 0.00 | 7.18M | -1.35M | 514.00K | 0.00 |
| Operating Expenses | 150.54M | 120.25M | 76.58M | 48.49M | 40.09M |
| Cost & Expenses | 150.54M | 120.25M | 76.58M | 48.49M | 40.09M |
| Interest Income | 10.70M | 4.60M | 148.00K | 236.00K | 1.05M |
| Interest Expense | 0.00 | 0.00 | 8.00K | 20.00K | 4.00K |
| Depreciation & Amortization | 3.53M | 3.64M | 984.00K | 900.00K | 751.00K |
| EBITDA | -112.53M | -104.78M | -66.00M | -35.21M | -30.21M |
| EBITDA Ratio | -326.40% | -767.21% | -710.34% | -278.89% | -561.63% |
| Operating Income | -116.06M | -106.40M | -66.98M | -36.12M | -34.31M |
| Operating Income Ratio | -336.63% | -768.17% | -697.84% | -292.24% | -592.69% |
| Total Other Income/Expenses | 14.18M | 7.05M | 377.00K | -3.00K | 3.34M |
| Income Before Tax | -101.88M | -99.35M | -66.60M | -36.13M | -30.97M |
| Income Before Tax Ratio | -295.49% | -717.28% | -693.92% | -292.27% | -535.04% |
| Income Tax Expense | 193.00K | 70.00K | 321.00K | -1.82M | -7.54M |
| Net Income | -102.07M | -99.42M | -66.92M | -34.31M | -23.43M |
| Net Income Ratio | -296.05% | -717.79% | -697.26% | -277.55% | -404.82% |
| EPS | -1.38 | -1.64 | -1.11 | -0.57 | -0.39 |
| EPS Diluted | -1.38 | -1.64 | -1.11 | -0.57 | -0.39 |
| Weighted Avg Shares Out | 73.81M | 60.80M | 60.26M | 59.97M | 59.97M |
| Weighted Avg Shares Out (Dil) | 73.81M | 60.80M | 60.26M | 59.97M | 59.97M |
All You Need to Know About Caribou Biosciences, Inc. (CRBU) Rating Upgrade to Buy
Why Caribou Biosciences Stock Is Crashing Today
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Caribou Biosciences to Participate in Upcoming Investor Conferences
2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare
3 Biotech Stocks You Can Buy and Hold for the Next Decade
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
3 Gene-Editing Stocks With the Potential to Mint Millionaires
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
Caribou Biosciences, Inc. (CRBU) Upgraded to Buy: What Does It Mean for the Stock?
Source: https://incomestatements.info
Category: Stock Reports